Has Heidi Fusco, MD received payments from drug or device companies?

Yes. Drug and device makers reported $152,658 in general payments to Heidi Fusco, MD across 270 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Heidi Fusco, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Heidi Fusco, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Heidi Fusco, MD

Physical Medicine & Rehabilitation · New York, NYNPI 1013177674

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $124,366 of the $152,658 with a category attached, or 81.5%. AbbVie accounts for 79.1% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $47,945 and has fallen 88.6% since, to $5,486 in 2025. Among physical medicine & rehabilitation clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$152,658in general payments, 2019–2025

Across 270 payments — averaging $565.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$121K
Merz North America, Inc.$19K
Avanir Pharmaceuticals, Inc.$8K
Ipsen Biopharmaceuticals, Inc$3K
Otsuka Pharmaceutical Development & Commercialization, Inc.$2K
Merz Pharmaceuticals, LLC$576
plus $441 from 1 others

$68,055in research payments, 2019–2025

Across 41 payments — averaging $1659.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Ipsen Pharma SAS$68K

What the payments were for

Consulting fees$15,39510%
Speaking & faculty fees$124,36681%
Travel & lodging$6,3514%
Food & beverage$6,3094%
Education$2370%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	204	$120,765
Merz North America, Inc.	33	$18,847
Avanir Pharmaceuticals, Inc.	13	$7,578
Ipsen Biopharmaceuticals, Inc	2	$2,550
Otsuka Pharmaceutical Development & Commercialization, Inc.	1	$1,900
Merz Pharmaceuticals, LLC	8	$576
Medtronic	9	$441

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

BOTOX$117,275
XEOMIN$18,652
DYSPORT$2,500
NUEDEXTA$125
LIORESAL$113

How this compares

$152,658 in reported general payments places this provider in the 95th percentile of 872 physical medicine & rehabilitation providers in New York.

See all physical medicine & rehabilitation providers in New York →

Medicare billing

Part B allowed, 2024

$149,046

Medicare patients

189

Services billed

10,235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Baclofen	38	$2,087
Tenofovir Disoproxil Fumarate	13	$2,040
AmantadineAmantadine Hcl	17	$820
Gabapentin	36	$694
Ezetimibe	24	$617
Methylphenidate Hcl	11	$611
Rosuvastatin Calcium	12	$459
Hydrocortisone	27	$248
Diazepam	28	$230
Memantine Hcl	14	$225
Trihexyphenidyl Hcl	13	$182
Sertraline Hcl	25	$147
Clotrimazole	12	$138
Atorvastatin Calcium	17	$135
Donepezil Hcl	11	$124

Paid to pharmacies, not to this prescriber.

Other physical medicine & rehabilitation in New York

Michael OdellNew York$67K
Craig AntellNew York$65K
Michael StubblefieldNew York$53K
Heakyung KimNew York$53K
Russell SilverNew York$34K
Julia IafrateNew York$32K
Neil JaseyNew York$29K
Christian CustodioNew York$19K
Karan JoharNew York$14K
Samantha ErosaNew York$14K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →